Full Text
The Full Text of this article is available as a PDF (314.3 KB).
References
- 1. Remme WJ: Towards the better treatment of heart failure. Eur Heart J 1998; 19 (suppl L): L36–L42 [PubMed] [Google Scholar]
- 2. Bart BA, Ertl G, Held P, Kuch J, Maggioni AP, McMurray J, Michelson EL, Rouleau JL, Stevenson LW, Swedberg K, Young JB, Yusuf S, Sellers MA, Granger CB, Califf RM, Pfeffer MA, for the SPICE investigators : Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999; 20: 1182–1190 [DOI] [PubMed] [Google Scholar]
- 3. The SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302 [DOI] [PubMed] [Google Scholar]
- 4. Dzau VJ: Angiotensin‐converting as a multimechanistic factor in CAD. J Myocard Ischemia 1995; 7: 6–14 [Google Scholar]
- 5. Francis GS: ACE inhibition in cardiovascular disease. N Engl J Med 2000; 342: 201–202 [DOI] [PubMed] [Google Scholar]
- 6. Raizada MK, Phillips MI, Sumners C: Cellular and molecular biology of the renin‐angiotensin system. Boca Raton, Fla: CRC Press, 1993. [Google Scholar]
- 7. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for the Randomized Aldactone Evaluation Study Investigators : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717 [DOI] [PubMed] [Google Scholar]
- 8. The Heart Outcomes Prevention Evaluation Study Investigators : Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. N Engl J Med 2000; 342: 145–153 [DOI] [PubMed] [Google Scholar]
- 9. The Heart Outcomes Prevention Evaluation Study Investigators : Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO‐HOPE substudy. Lancet 2000; 355: 253–259 [PubMed] [Google Scholar]
- 10. Remme WJ: Prevention of worsening heart failure: Future focus. Eur Heart J 1998; 19 (suppl B): B47–B53 [PubMed] [Google Scholar]
- 11. Garg G, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials : Overview of randomized trials of angiotensin‐converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J Am Med Assoc 1995; 273: 1450–1456 [PubMed] [Google Scholar]
- 12. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators : Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–828 [PubMed] [Google Scholar]
- 13. Vaughan DE: Fibrinolytic balance, the renin‐angiotensin system and atherosclerotic disease. Eur Heart J 1998; 19 (suppl G): G9–G12 [PubMed] [Google Scholar]
- 14. Vaughan DE, Rouleau JL, Ridker PM, Arnold JMO, Menapace FJ, Pfeffer MA, for the HEART Study Investigators : Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997; 96: 442–447 [DOI] [PubMed] [Google Scholar]
- 15. Saksela O, Rifkin DB: Cell‐associated plasminogen activation: Regulation and physiologic functions. Am Rev Cell Biol 1988; 4: 93–126 [DOI] [PubMed] [Google Scholar]
- 16. Libby P: Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844–2850 [DOI] [PubMed] [Google Scholar]
- 17. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3–9 [DOI] [PubMed] [Google Scholar]
- 18. Hamsten A, Wiman B, de Faire U, Blomback M: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557–1563 [DOI] [PubMed] [Google Scholar]
- 19. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin‐angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969–1973 [DOI] [PubMed] [Google Scholar]
- 20. Kerins DM, Hao Q, Vaughan DE: Angiotensin induction of PAI‐1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96: 2515–2520 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Brown NJ, Nadeau JH, Vaughan DE: Selective stimulation of tissue‐type plasminogen activator (t‐PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77: 522–525 [PubMed] [Google Scholar]
- 22. White CM: Pharmacologic, pharmacokinetic and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998; 18: 588–599 [PubMed] [Google Scholar]